

# Review of: "Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants"

Erik De Clercq<sup>1</sup>

<sup>1</sup> Slovak Medical University

**Potential competing interests:** The author(s) declared that no potential competing interests exist.

I rarely had a paper for review that was as perfectly constructed as this one. Although the soft deadline of 6 weeks was advised, I wanted you to know that I highly recommend this paper for publication without further delay. Thank you for asking my advice.

P.S.: You mentioned a previous mail of 17 March, but I did not receive it.